SCHEMBL3409832

SCHEMBL3409832

O=C(O)Oc1cc2cc(OCc3ccccc3)ccc2[nH]1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.68
HPGD P15428 2/20 0.68
SRD5A2 P31213 2/20 0.68
KDM4E B2RXH2 1/20 0.68
CYP1A2 P05177 1/20 0.68
CYP2C9 P11712 1/20 0.68
HSD17B10 Q99714 1/20 0.68
PDGFRB P09619 1/20 0.64
PDGFRA P16234 1/20 0.64
FLT3 P36888 1/20 0.57
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
CFD P00746 1/20 0.52
ALOX5 P09917 1/20 0.51
MAOB P27338 3/20 0.50
MAOA P21397 2/20 0.50
AURKA O14965 1/20 0.47
KDR P35968 1/20 0.47
MDH2 P40926 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3416355 0.90 FLT3 (0.57) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL27635516 0.88 SRD5A2 (0.62) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL8111841 0.87 KDM4E (0.52) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL18886838 0.87 ALDH1A1 (0.61) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL630515 0.81 SRD5A2 (1.00) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL6660937 0.80 HTT (0.49) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL15141030 0.79 SRD5A2 (0.68) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL6089719 0.79 KDM4E (0.81) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL13133298 0.79 KDM4E (0.81) ALDH1A1HPGDSRD5A2KDM4ECYP1A2
SCHEMBL18733286 0.78 KDM4E (0.79) ALDH1A1HPGDSRD5A2KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2149552-A1 5,6 substituted benzamide derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP claimed
EP-1599203-B1 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2013-10-23 EP disclosed
EP-1261585-B1 SUBSTITUTED INDOLE MANNICH BASES GRUENENTHAL GMBH (DE) 2007-09-26 EP disclosed
EP-1599203-A1 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-30 EP disclosed
WO-2004075891-A1 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-10 WO disclosed
EP-1261585-A1 SUBSTITUTED INDOLE MANNICH BASES Grünenthal GmbH (DE) 2002-12-04 EP disclosed
WO-2001047885-A1 SUBSTITUTED INDOLE MANNICH BASES Grünenthal GmbH (DE) 2001-07-05 WO disclosed